ESPR — Esperion Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Feb 17, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion announced a settlement agreement with Alkem Laboratories Ltd. to prevent the marketing of generic versions of NEXLETOL and NEXLIZET in the United States until April 19, 2040. This is the fifth ANDA filer to reach such an agreement with Esperion. Patent litigation against four remaining defendants (Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc.) continues with uncertain outcomes.

SDZNY ESPR patent settlement generic drugs NEXLETOL NEXLIZET ANDA litigation bempedoic acid

Sentiment note

Esperion secured another settlement extending market exclusivity for its key products until 2040, protecting revenue streams. The company has now settled with five ANDA filers, reducing competitive threats and demonstrating successful patent defense strategy.

Positive Nov 21, 2025 • 13:00 UTC GlobeNewswire Inc. • Sheldon Koenig

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion announced that its partner Otsuka launched NEXLETOL in Japan, receiving a $90 million payment for the cardiovascular prevention drug's national health insurance price listing and market entry.

ESPR NEXLETOL cardiovascular prevention hypercholesterolemia Japan market pharmaceutical partnership

Sentiment note

Received significant milestone payment, expanded market presence in Japan's third-largest cardiovascular prevention market

Positive Nov 18, 2025 • 12:00 UTC GlobeNewswire Inc. • Esperion

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

HLS Therapeutics received Health Canada approval to market NILEMDO® for reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease, with commercial launch expected in Q2 2026.

ESPR NILEMDO LDL-Cholesterol cardiovascular disease Canada drug approval

Sentiment note

Achieved regulatory approval in Canada, expanding market access for their cholesterol-lowering medication

Positive Nov 4, 2025 • 13:00 UTC GlobeNewswire Inc. • Esperion Therapeutics

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion announced the appointment of John Harlow as Chief Commercial Officer, bringing over two decades of pharmaceutical leadership experience to drive commercial strategies and global expansion of cardiovascular risk reduction therapies.

ESPR pharmaceutical leadership cardiovascular commercial strategy executive appointment

Sentiment note

Company is expanding leadership, bringing in an experienced executive with proven track record of revenue growth and commercial transformation

Positive Oct 27, 2025 • 12:00 UTC GlobeNewswire Inc. • Esperion Therapeutics

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Esperion will present two research analyses at the AHA Scientific Sessions in New Orleans, focusing on bempedoic acid's impact on LDL cholesterol and cardiovascular events, including a monotherapy analysis and a study on venous thromboembolism.

ESPR bempedoic acid LDL cholesterol cardiovascular events clinical research medical conference

Sentiment note

Company is presenting new research analyses at a major medical conference, demonstrating ongoing clinical research and potential expansion of treatment options for cardiovascular disease patients

Neutral Oct 8, 2025 • 01:29 UTC GlobeNewswire Inc. • Esperion Therapeutics, Inc.

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Therapeutics plans to raise approximately $75 million through a public offering of 30 million shares at $2.50 per share, with underwriters having an option to purchase an additional 4.5 million shares.

ESPR PIPR public offering stock sale fundraising biopharmaceutical

Sentiment note

The company is conducting a standard public stock offering to raise capital, which is a common financial strategy for biopharmaceutical firms. The neutral sentiment reflects a routine business transaction without significant positive or negative implications.

Neutral Oct 7, 2025 • 20:01 UTC Benzinga • Globe Newswire

Esperion Announces Proposed Public Offering of Common Stock

Esperion Therapeutics plans to conduct an underwritten public offering of common stock, with Piper Sandler and Cantor Fitzgerald as joint book-running managers. The offering is subject to market conditions and will be made through a prospectus supplement.

ESPR PIPR public offering common stock biopharmaceutical LDL-C cholesterol

Sentiment note

The company is conducting a standard public offering to raise capital, which is a typical financial strategy for biopharmaceutical firms. The neutral sentiment reflects the routine nature of the stock offering without indicating significant positive or negative implications.

Positive Oct 3, 2025 • 12:00 UTC GlobeNewswire Inc. • Esperion Therapeutics

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Esperion has settled patent litigation with Dr. Reddy's Laboratories, agreeing that generic versions of NEXLETOL and NEXLIZET will not be marketed in the US before April 19, 2040.

RDY ESPR patent settlement generic drugs pharmaceutical litigation cholesterol medication

Sentiment note

Successfully defended patent rights and secured agreement preventing generic competition until 2040

Positive Sep 19, 2025 • 12:00 UTC GlobeNewswire Inc. • Esperion

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion's partner Otsuka received Japanese regulatory approval to market NEXLETOL, a non-statin cholesterol treatment, expanding the drug's global market presence in the third-largest cardiovascular prevention market.

ESPR NEXLETOL hypercholesterolemia regulatory approval Japan cardiovascular prevention

Sentiment note

Received regulatory approval in Japan, expanding global market reach and potential revenue through milestone payments and royalties

Positive Aug 5, 2025 • 10:00 UTC GlobeNewswire Inc. • Esperion Therapeutics

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion reported Q2 2025 total revenue growth of 12% to $82.4 million, with U.S. net product revenue increasing 42% year-over-year. The company achieved its first quarter of operating income and expects sustainable profitability starting in Q1 2026, driven by strong commercial execution and cardiovascular disease prevention therapies.

ESPR DSNKY bempedoic acid cardiovascular disease pharmaceutical revenue growth profitability

Sentiment note

Strong revenue growth, first quarter of operating income, expanding global partnerships, and projected sustainable profitability indicate positive business performance

Positive May 9, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

Esperion, a commercial-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The company will provide a live webcast of the event on its investor and media section.

ESPR Esperion investor conference webcast

Sentiment note

The article highlights Esperion's participation in an investor conference, which suggests the company is actively engaging with the investment community and providing updates on its business.

Positive Apr 24, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion announced new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver disease. The company's next-generation ACLY inhibitor discovery program has shown promising preclinical results in reducing liver injury, inflammation, and fibrosis.

ESPR Esperion primary sclerosing cholangitis ACLY inhibitor liver disease

Sentiment note

The article highlights Esperion's promising research and development efforts in the field of primary sclerosing cholangitis, a rare and progressive liver disease. The company's next-generation ACLY inhibitor program has shown positive preclinical results, indicating the potential for a new treatment approach.